IGHV2OR16-5

Across TCGA pan-cancer cohorts, IGHV2OR16-5 RNA differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of IGHV2OR16-5’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where IGHV2OR16-5 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types IGHV2OR16-5 is over-expressed in tumor, although a few such as COAD and PAAD show the opposite, repressed pattern.

LUAD, COAD, and PAAD are the cancer types where IGHV2OR16-5 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in IGHV2OR16-5 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	All	All	+0.440	<.001	9	view →
COAD	Female	II,III,IV	−0.418	.003	5	view →
PAAD	All	All	−0.200	.030	4	view →
BRCA	Female	II,III,IV	−0.156	<.001	4	view →
KIRC	All	All	+0.120	.006	4	view →
READ	Female	All	−0.655	.011	2	view →
STAD	All	IV	−1.443	.020	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

IGHV2OR16-5–LUAD

Open the LUAD breakdown →